Lupin Digital Health has announced results from a one-year-long study, showing the efficacy of their digital therapeutics (DTx) platform among patients with acute coronary syndrome (ACS) and post-percutaneous coronary interventions. Lupin Digital Health is a subsidiary of Lupin, a global pharmaceutical company, focused on providing digital solutions to address unmet patient needs. Lupin Digital Health’s DTx, Lyfe is a heart care program that reduces the risk of heart attack and improves quality of life to cardiac patients and is India’s first evidence-based DTx solution.
The study aimed to evaluate the efficacy of Lyfe, on cardiovascular events, hospital readmissions, medication adherence, vital sign monitoring, and lifestyle changes among heart patients. During the 90-day interim analysis it was found that those enrolled showed significant improvements, including 90% adherence to the prescribed recommended diet, medication, and exercise. Furthermore, 83.3% of patients' vital signs were maintained within the normal range, and there were no hospital readmissions within the first 30 days.
“We are excited to share the positive outcomes of India’s first digital therapeutics study. The study’s outcomes showcase the effectiveness of our evidence-based and comprehensive heart care program in ensuring high adherence and low re-hospitalisation for patients,” said Sidharth Srinivasan, CEO, Lupin Digital Health.
Click here to read the original news story.